Limits...
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.

Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW - Br. J. Cancer (2002)

Bottom Line: The median time to disease progression was 6.4 months, median survival from start of treatment 11.2 months, and median survival from diagnosis 17.3 months.Major toxicities were haematological, limiting the mean relative dose intensity of gemcitabine to 75%.This schedule of cisplatin and gemcitabine is active in malignant mesothelioma in a multicentre setting.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Sir Charles Gairdner Hospital, Verdun Street, Nedlands, WA 6009 Australia.

ABSTRACT
Our previous phase II study of cisplatin and gemcitabine in malignant mesothelioma showed a 47.6% (95% CI 26.2-69.0%) response rate with symptom improvement in responding patients. Here we confirm these findings in a multicentre setting, and assess the effect of this treatment on quality of life and pulmonary function. Fifty-three patients with pleural malignant mesothelioma received cisplatin 100 mg m(-2) i.v. day 1 and gemcitabine 1000 mg m(-2) i.v. days 1, 8, and 15 of a 28 day cycle for a maximum of six cycles. Quality of life and pulmonary function were assessed at each cycle. The best response achieved in 52 assessable patients was: partial response, 17 (33%, 95% CI 20-46%); stable disease, 31 (60%); and progressive disease, four (8%). The median time to disease progression was 6.4 months, median survival from start of treatment 11.2 months, and median survival from diagnosis 17.3 months. Vital capacity and global quality of life remained stable in all patients and improved significantly in responding patients. Major toxicities were haematological, limiting the mean relative dose intensity of gemcitabine to 75%. This schedule of cisplatin and gemcitabine is active in malignant mesothelioma in a multicentre setting. Investigation of alternative scheduling is needed to decrease haematological toxicity and increase the relative dose intensity of gemcitabine whilst maintaining response rate and quality of life.

Show MeSH

Related in: MedlinePlus

Global health status over six cycles of chemotherapy. Responding patients had a significantly improved global quality of life during treatment as compared with non-responders (P=0.008).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376155&req=5

fig4: Global health status over six cycles of chemotherapy. Responding patients had a significantly improved global quality of life during treatment as compared with non-responders (P=0.008).

Mentions: Among responding patients there was a significant improvement in the EORTC-QLQ-C30 global QOL scale (P=0.006) compared to non-responding patients over six cycles of chemotherapy (Figure 4Figure 4


A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.

Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW - Br. J. Cancer (2002)

Global health status over six cycles of chemotherapy. Responding patients had a significantly improved global quality of life during treatment as compared with non-responders (P=0.008).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376155&req=5

fig4: Global health status over six cycles of chemotherapy. Responding patients had a significantly improved global quality of life during treatment as compared with non-responders (P=0.008).
Mentions: Among responding patients there was a significant improvement in the EORTC-QLQ-C30 global QOL scale (P=0.006) compared to non-responding patients over six cycles of chemotherapy (Figure 4Figure 4

Bottom Line: The median time to disease progression was 6.4 months, median survival from start of treatment 11.2 months, and median survival from diagnosis 17.3 months.Major toxicities were haematological, limiting the mean relative dose intensity of gemcitabine to 75%.This schedule of cisplatin and gemcitabine is active in malignant mesothelioma in a multicentre setting.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Sir Charles Gairdner Hospital, Verdun Street, Nedlands, WA 6009 Australia.

ABSTRACT
Our previous phase II study of cisplatin and gemcitabine in malignant mesothelioma showed a 47.6% (95% CI 26.2-69.0%) response rate with symptom improvement in responding patients. Here we confirm these findings in a multicentre setting, and assess the effect of this treatment on quality of life and pulmonary function. Fifty-three patients with pleural malignant mesothelioma received cisplatin 100 mg m(-2) i.v. day 1 and gemcitabine 1000 mg m(-2) i.v. days 1, 8, and 15 of a 28 day cycle for a maximum of six cycles. Quality of life and pulmonary function were assessed at each cycle. The best response achieved in 52 assessable patients was: partial response, 17 (33%, 95% CI 20-46%); stable disease, 31 (60%); and progressive disease, four (8%). The median time to disease progression was 6.4 months, median survival from start of treatment 11.2 months, and median survival from diagnosis 17.3 months. Vital capacity and global quality of life remained stable in all patients and improved significantly in responding patients. Major toxicities were haematological, limiting the mean relative dose intensity of gemcitabine to 75%. This schedule of cisplatin and gemcitabine is active in malignant mesothelioma in a multicentre setting. Investigation of alternative scheduling is needed to decrease haematological toxicity and increase the relative dose intensity of gemcitabine whilst maintaining response rate and quality of life.

Show MeSH
Related in: MedlinePlus